The role of PPARγ ligands as regulators of the immune response

Drug News and Perspectives

Volumn 15, Issue 6, 2002, Pages 325-332

  Kwak, Brenda R ^a   Mulhaupt, Flore ^a   Mach, François ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CD40 ANTIGEN; CD40 LIGAND; CIGLITAZONE; CYTOKINE; GAMMA INTERFERON; IBUPROFEN; INDOMETACIN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN F2 ALPHA; ROSIGLITAZONE; TROGLITAZONE;

ADIPOCYTE; ALLOGRAFT; ANTIGEN EXPRESSION; ARTICLE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOREGULATION; MACROPHAGE ACTIVATION; T LYMPHOCYTE ACTIVATION; VASCULAR DISEASE;

EID: 0036657480     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2002.15.6.701652     Document Type: Article

References (110)

1. Isseman, I. and Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347: 645-50.
2. Schoonjans, K., Staels, B. and Auwerx, J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996, 1302: 93-109.
3. Desvergne, B. and Wahli, W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 1999, 20: 649-88.
4. Mangelsdorf, D.J., Thummel, C., Beato, M. et al. The nuclear receptor superfamily: The second decade. Cell 1995, 83: 835-9.
5. Giguere, V. Orphan nuclear receptors: From gene to function. Endocr Rev 1999, 20: 689-725.
6. Cullingford, T.E., Bhakoo, K., Peuchen, S. et al. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J Neurochem 1998. 70: 1366-75.
7. Braissant, O. and Wahli, W. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 1998, 139: 2748-54.
8. Fruchart, J.C., Staels, B. and Duriez P. PPARs, metabolic disease and atherosclerosis. Pharmacol Res 2001, 44: 345-52.
9. Pineda Torra, I., Gervois, P. and Staels, B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr Opin Lipidol 1999, 10: 151-9.
10. Rocchi, S. and Auwerx, J. Peroxisome proliferator-activated receptor-gamma: A versatile metabolic regulator Ann Med 1999, 31: 342-51.
11. Kersten, S., Desvergne, B. and Wahli, W. Roles of PPARs in health and disease. Nature 2000, 405: 421-4.
12. Vamecq, J. and Latruffe, N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999, 354: 141-8.
13. Glass, C.K. Potential roles of the peroxisome proliferator-activated receptor-gamma in macrophage biology and atherosclerosis. J Endocrinol 2001, 169: 461-4.
14. Neve, B.P., Fruchart, J.C. and Staels, B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000, 60: 1245-50.
15. Marx, N. Peroxisome proliferator-activated receptor gamma and atherosclerosis. Curr Hypertens Rep 2002, 4: 71-7.
16. Hsueh, W.A. and Law. R.E. PPARgamma and atherosclerosis: Effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001, 21: 1891-5.
17. Fajas, L., Debril, M.B. and Auwerx, J. Peroxisome proliferator-activated receptor-gamma: From adipogenesis to carcinogenesis. J Mol Endocrinol 2001, 27: 1-9.
18. Roberts-Thomson, S.J. Peroxisome proliferator-activated receptors in tumorigenesis: Targets of tumour promotion and treatment. Immunol Cell Biol 2000, 78: 436-41.
19. Vanden Heuvel, J.P. Peroxisome proliferator-activated receptors (PPARs) and carcinogenesis. Toxicol Sci 1999, 47: 1-8.
20. Gonzalez, F.J. The role of peroxisome proliferator activated receptor alpha in peroxisome proliferation, physiological homeostasis, and chemical carcinogenesis. Adv Exp Med Biol 1997, 422: 109-25.
21. DiRenzo, J., Soderstrom, M., Kurokawa, R. et al. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors. Mol Cell Biol 1997, 17: 2166-76.
22. Ijpenberg, A., Jeannin, E., Wahli, W. et al. Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem 1997, 272: 20108-17.
23. Uppenberg, J., Svensson, C., Jaki, M. et al. Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J Biol Chem 1998, 273: 31108-12.
24. Nolte, R.T., Wisely, G.B., Westin, S. et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998, 395: 137-43.
25. Nakshatri, H. and Bhat-Nakshatri, P. Multiple parameters determine the specificity of transcriptional response by nuclear receptors HNF-4, ARP-1, PPAR, RAR and RXR through common response elements. Nucleic Acids Res 1998, 26: 2491-9.
26. Palmer, C.N., Hsu M.H., Griffin, H.J. et al. Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem 1995, 270: 16114-21.
27. Juge-Aubry, C., Pernin, A., Favez, T. et al. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5′-flanking region. J Biol Chem 1997, 272: 25252-9.
28. Hsu, M.H., Palmer, C.N., Song, W. et al. A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding. J Biol Chem 1998, 273: 27988-97.
29. Gulick, T., Cresci, S., Caira, T. et al. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 1994, 91: 11012-6.
30. Keller, H., Dreyer, C., Medin, J. et al. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 1993, 90: 2160-4.
31. Tontonoz, P., Hu, E. and Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPARgamma 2, a lipid-activated transcription factor. Cell 1994, 79: 1147-56.
32. Zhang, B., Berger, J., Hu, E. et al. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol Endocrinol 1996, 10: 1457-66.
33. Lehmann, J.M., Lenhard, J.M., Oliver, B.B. et al. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997, 272: 3406-10.
34. Rosen, E.D., Sarraf, P., Troy, A.E. et al. PPARgamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999, 4: 611-7.
35. Wu, Z., Rosen, E.D., Brun, R. et al. Cross-regulation of C/EBP alpha and PPARgamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 1999, 3: 151-8.
36. Kubota, N., Terauchi, Y., Miki, H. et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999, 4: 597-609.
37. Barak, Y., Nelson, M.C., Ong, E.S. et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999, 4: 585-95.
38. Ricote, M., Li, A.C., Willson, T.M. et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391: 79-82.
39. Jiang, C., Ting, A.T. and Seed, B. PPARgamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391: 82-6.
40. Staels, B., Koenig, W., Habib, A. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393: 790-3.
41. Barak, Y., Liao, D., He, W. et al. Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 2002, 99: 303-8.
42. Fajas, L., Auboeuf, D., Raspe, E. et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997, 272: 18779-89.
43. Fajas, L., Fruchart, J.C. and Auwerx, J. PPARgamma3 mRNA: A distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 1998, 438: 55-60.
44. Forman, B.M., Tontonoz, P., Chen, J. et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83: 803-12.
45. Rossi, A., Kapahi, P., Natoli, G. et al. Antiinflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 2000, 403: 103-8.
46. Straus, D.S., Pascual, G., Li, M. et al. 15-deoxy-delta 12,14-prostoglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 2000, 97: 4844-9.
47. Nagy, L., Tontonoz, P., Alvarez, J.G. et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998, 93: 229-40.
48. Tontonoz, P., Nagy, L., Alvarez, J.G. et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93: 241-52.
49. Delerive, P., Furman, C., Teissier, E. et al. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner FEBS Lett 2000, 47 1: 34-8.
50. Henry, R.R. Thiazolidinediones. Endocrinol Metab Clin North Am 1997, 26: 553-73.
51. Willson, T.M., Lehmann, J.M. and Kliewer, S.A. Discovery of ligands for the nuclear peroxisome proliferator-activated receptors. Ann NY Acad Sci 1996, 804: 276-83.
52. Willson, T.M., Brown, P.J. Sternbach, D.D. et al. The PPARs: From orphan receptors to drug discovery. J Med Chem 2000, 43: 527-50.
53. Willson, T.M., Cobb, J.E., Cowan, D.J. et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996, 39: 665-8.
54. Lehmann, J.M., Lenhard, J.M., Oliver, B.B. et al. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1997, 272: 3406-10.
55. Benacerraf, B. Role of MHC gene products in immune regulation. Science 1981, 212: 1229-38.
56. Trowsdale, J. Genomic structure and function in the MHC. Trends Genet 1993, 9: 117-22.
57. Janeway, C.A., Jr., Carding, S., Jones, B. et al. CD4+ T cells: Specificity and function. Immunol Rev 1988, 101: 39-80.
58. Janeway, C.A., Jr. and Bottomly, K. Signals and signs for lymphocyte responses. Cell 1994, 76: 275-85.
59. Scholl, P.R. and Geha, R.S. MHC class II signaling in B-cell activation. Immunol Today 1994, 15: 418-22.
60. Benoist, C. and Mathis, D. Regulation of major histocompatibility complex class-II genes: X, Y and other letters of the alphabet. Annu Rev Immunol 1990, 8: 681-715.
61. Glimcher, L.H. and Kara, C.J. Sequences and factors: A guide to MHC class-II transcription. Annu Rev Immunol 1992, 10: 13-49.
62. Ting, J.P. and Baldwin, A.S. Regulation of MHC gene expression. Curr Opin Immunol 1993, 5: 8-16.
63. Mach, B., Steimle, V., Martinez-Soria, E. et al. Regulation of MHC class II genes: Lessons from a disease. Annu Rev Immunol 1996, 14: 301-31.
64. Boss, J.M. Regulation of transcription of MHC class II genes. Curr Opin Immunol 1997, 9: 107-13.
65. DeSandro, A., Nagarajan, U.M. and Boss, J.M. The bare lymphocyte syndrome: Molecular clues to the transcriptional regulation of major histocompatibility complex class II genes. Am J Hum Genet 1999, 65: 279-86.
66. Reith, W. and Mach, B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 2001, 19: 331-73.
67. Masternak, K., Muhlethaler-Mottet, A., Villard, J. et al. Molecular genetics of the bare lymphocyte syndrome. Rev Immunogenet 2000, 2: 267-82.
68. Durand, B., Sperisen, P., Emery, P. et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J 1997, 16: 1045-55.
69. Steimle, V., Durand, B., Barras, E. et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 1995, 9: 1021-32.
70. Masternak, K., Barras, E., Zufferey, M. et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998, 20: 273-7.
71. Steimle, V., Otten, L.A., Zufferey, M. et al. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993, 75: 135-46.
72. Otten, L.A., Steimle, V., Bontron, S. et al. Quantitative control of MHC class II expression by the transactivator CIITA. Eur J Immunol 1998, 28: 473-8.
73. Muhlethaler-Mottet, A., Otten, L.A., Steimle, V. et al. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differ ential usage of multiple promoters of the transactivator CIITA. EMBO J 1997, 16: 2851-60.
74. Muhlethaler-Mottet, A., Di Berardino, W., Otten, L.A. et al. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 1998, 8: 157-66.
75. Li, A.C., Brown, K.K., Silvestre, M.J. et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000, 106: 523-31.
76. Collins, A.R., Meehan, W.P., Kintscher, U. et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density tipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21: 365-71.
77. Hansson, G.K., Jonasson, L., Lojsthed, B. et al. Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Atherosclerosis 1988, 72: 135-41.
78. Hansson, G.K. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol 1997, 8: 301-11.
79. Witztum, J.L. and Palinski, W. Are immunological mechanisms relevant for the development of atherosclerosis? Clin Immunol 1999, 90: 153-6.
80. Hansson, G.K., Holm, J. and Jonasson, L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989, 135: 169-75.
81. Van der Wal, A.C., Das, P.K., Bentz van de Berg, D. et al. Atherosclerotic lesions in humans: In situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989, 61: 166-70.
82. Zhou, X., Stemme, S. and Hansson, G.K. Evidence for a local immune response in atherosclerosis: CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol 1996, 149: 359-66.
83. Mach, F., Schonbeck, U., Sukhova, G.K. et al. Functional CD40 is expressed on human vascular endothelial cells, smooth muscle cells, and macrophage: Implication for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997, 94: 1931-6.
84. Mach, F., Schonbeck, U., Sukhova, G.K. et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998, 394: 200-3.
85. Lutgens, E., Gorelik, L., Daemen, M.J. et al. Requirement for CD154 in the progression of atherosclerosis. Nature Med 1999, 5: 1313-6.
86. Jonassom, L., Holm, J., Skalli, O. et al. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985, 76: 125-31.
87. Whitman, S.C., Ravisankar, P., Elam, H. et al. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am J Pathol 2000, 157: 1819-24.
88. Kwak, B.R., Myit, S., Mulhaupt, F. et al. PPARgamma but not PPARalpha ligands are potent repressors of major histocompatibility complex class II induction in atheroma-associated cells. Circ Res 2002, 90: 356-62.
89. Frostegard, J., Ulfgren, A.K., Nyberg, P. et al. Cytokine expression in advanced human atherosclerotic plaques: Dominance of proinflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999, 145: 33-43.
90. Marx, N., Kehrle, B., Kohlhammer, K. et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: Implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002, 90: 703-10.
91. Yang, X.Y., Wang, L.H., Chen, T. et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000, 275: 4541-4.
92. Clark, R.B., Bishop-Bailey, D., EstradaHernandez, T. et al. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000, 164: 1364-71.
93. Clark, R.B. The role of PPARs in inflammation and immunity. J Leukoc Biol 2002, 71: 388-400.
94. Yang, X.Y., Wang, L.H., Mihalic, K. et al. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands. J Biol Chem 2002, 277: 3973-8.
95. Gordon, S. The macrophage. Bioessays 1995, 17: 977-86.
96. Ross, R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999, 340: 115-26.
97. Raines, E.W. and Ross, R. Is overamplification of the normal macrophage defensive role critical to lesion development? Ann NY Acad Sci 1997, 811: 76-87.
98. Kinne, R.W., Brauer, R., Stuhlmuller, B. et al. Macrophages in rheumatoid arthritis. Arthritis Res 2000, 2: 189-202.
99. Morhenn, V.B. Langerhans cells may trigger the psoriatic disease process via production of nitric oxide. Immunol Today 1997, 18: 433-6.
100. Stoll, G. and Jander, S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol 1999, 58: 233-47.
101. Mahida, Y.R. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000, 6: 21-33.
102. Moore, K.J., Fitzgerald, M.L. and Freeman, M.W. Peroxisome proliferator-activated receptors in macrophage biology: Friend or foe? Curr Opin Lipidol 2001, 12: 519-27.
103. Landreth, G.E. and Heneka, M.T. Antiinflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 2001, 22: 937-44.
104. Ricote, M., Huang, J., Fajas, L. et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 1998, 95: 7614-9.
105. Moore, K.J., Rosen. E.D., Fitzgerald, M.L. et al. The role of PPARgamma in macrophage differentiation and cholesterol uptake. Nature Med 2001, 7: 41-7.
106. Chawla, A., Barak, Y., Nagy, L. et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nature Med 2001, 7: 48-52.
107. Combs, C.K., Johnson, D.E., Karlo, J.C. et al. Inflammatory mechanisms in Alzheimer's disease: Inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 2000, 20: 558-67.
108. Thieringer, R., Fenyk-Melody, J.E., Le Grand, C.B. et al. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha reponses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol 2000, 164: 1046-54.
109. Minamikawa, J., Tanaka, S., Yamauchi, M. et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998, 83: 1818-20.
110. Spore, M.B., Suh, N. and Mangelsdoff, D.J. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). Trends Mol Med 2001, 7: 395-400.